Ginsenoside Rg1

Catalog No.S3923 Batch:S392302

Technical Data

Formula	C₄₂H₇₂O₁₄
Molecular Weight	801.01	CAS No.	22427-39-0
Solubility (25°C)*	In vitro


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Biological Activity

Description

Ginsenoside Rg1 (Ginsenoside A2, Panaxoside A, Panaxoside Rg1, Sanchinoside C1, Sanchinoside Rg1), one of the major active components of ginseng, is identified as a protopanaxatriol-type and has pharmacological actions such as neuroprotective and anti-tumor effects on various cancer types. Ginsenoside Rg1 reduces cerebral Aβ levels and NF-κB nuclear translocation.

Targets

Aβ ^[5]

NF-κB ^[6]

In vitro

Ginsenoside Rg1 (Rg1) activates promyogenic kinases, p38MAPK (mitogen-activated protein kinase) and Akt signaling, that in turn promotes the heterodimerization with MyoD and E proteins, resulting in enhancing myogenic differentiation. Through the activation of Akt/mammalian target of rapamycin pathway, Rg1 induces myotube growth and prevents dexamethasone-induced myotube atrophy. Furthermore, Rg1 increases MyoD-dependent myogenic conversion of fibroblast. Rg1 enhances glucose uptake in insulin-resistant myoblasts^[1]. Rg1 possesses the capacity for anti-aging activity in HSCs both in vitro and vivo^[2]. Ginsenoside Rg1 promotes endothelial progenitor cells (EPCs) adhesion, proliferation, migration and in vitro vasculogenesis in a dose- and time-dependent manner^[3]. Ginsenoside Rg1 could prevent cellular apoptosis via initiating an autophagic survival response, during which time Rg1 could promote the expression of Beclin1 and Bcl-2 and weaken the interaction between Beclin1 and Bcl-2^[4].

In vivo

Rg1 can protect BMSCs against senescence and affect cell cycle phase distribution of bone marrow stromal cells (BMSCs) in aged rats. It affects inflammatory cytokine and stem cell factor (SCF) levels of BMSCs. Rg1 affects inflammatory cytokine and SCF levels of BMSCs. Rg1 improves the anti-aging ability of hematopoietic microenvironment through enhancing the anti-oxidant and anti-inflammatory capacities of BMSCs^[2]. Rg1 has neuroprotective properties in neurodegenerative diseases such as AD. Rg1 could ameliorate cognitive impairment in the mouse model of AD, improve the learning and memory abilities, decrease the levels of cerebral Aβ, maintain hippocampal neuron activity, and prevent cellular apoptosis induced by Aβ accumulation. On the other hand, Rg1 also could protect against brain aging by enhancing the scavenging of free radicals in the brain^[5].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Myoblast C2C12 cells Concentrations 1, 5, 10, 50 nM Incubation Time 2 days Method For the induction of myogenic differentiation, C2C12 cells are exchanged from growth medium (GM) containing 15% FBS to differentiation medium (DM) containing 2% HS. The efficiency of the myoblast differentiation is quantified. To induce hypertrophic myoblast differentiation, C2C12 cells are differentiated for 2 d and then treated with Rg1 for additional 2 days in DM. For the DEX-induced atrophy study, C2C12 cells are triggered to differentiate for 24 hrs and treated with 25 μM DEX and 10 nM Rg1, followed by incubation in DM for 2 days.
Animal Study:^{^[2]}	Animal Models male Sprague-Dawley rats Dosages 20 mg/kg·d Administration i.p.

Cell Assay:^{^[1]}

Cell lines
Myoblast C2C12 cells
Concentrations
1, 5, 10, 50 nM
Incubation Time
2 days
Method
For the induction of myogenic differentiation, C2C12 cells are exchanged from growth medium (GM) containing 15% FBS to differentiation medium (DM) containing 2% HS. The efficiency of the myoblast differentiation is quantified. To induce hypertrophic myoblast differentiation, C2C12 cells are differentiated for 2 d and then treated with Rg1 for additional 2 days in DM. For the DEX-induced atrophy study, C2C12 cells are triggered to differentiate for 24 hrs and treated with 25 μM DEX and 10 nM Rg1, followed by incubation in DM for 2 days.

Animal Study:^{^[2]}

Animal Models
male Sprague-Dawley rats
Dosages
20 mg/kg·d
Administration
i.p.

References

+ Expand

Selleck's Ginsenoside Rg1 has been cited by 2 publications

Ginsenoside Rg1 promotes astrocyte-to-neuron transdifferentiation in rat and its possible mechanism [ CNS Neurosci Ther, 2022, 10.1111/cns.14000]	PubMed: 36352836
Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo [ J Ethnopharmacol, 2021, S0378-8741(21)00169-0]	PubMed: 33617967

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.